Analysts See Japan’s Biggest Drug Industry Loss By Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is expected to report the biggest annual loss of any Japanese drug maker, with a 2008 deficit of $3.2 billion. Six analysts surveyed for their estimates provided a median estimate for the amount of loss. The steep drop was caused primarily by write-downs Daiichi Sankyo had to take for its takeover of Ranbaxy Laboratories. A Daiichi Sankyo spokeswoman declined to comment ahead of a scheduled release of the firm's earnings report. The company forecast in October a net income for the year, before it announced the write-downs. (Click here for more
You may also be interested in...
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
Daiichi Sankyo Streamlines Corporate, R&D Organizations
TOKYO - As part of the process of giving the finishing touches on the merger of the former Daiichi and Sankyo pharmaceutical companies, Daiichi Sankyo, the second-largest Japanese pharmaceutical firm, will revamp its corporate and research and development divisions, effective April 1, the company announced Feb. 22. The reorganization in part is aimed at boosting its global presence by proactively mobilizing Indian subsidiary Ranbaxy resources, a company spokesman explained Feb. 23
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.